hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction. hC’s innovations in precision protein editing therapies target genetically defined diseases.  A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.  



Cambridge, MA, USA

hC Bioscience

A Silicon Valley venture capital firm dedicated to creating value through technology.

Join us